Joseph P. Bressler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joseph P. Bressler has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Luisa Olivi
School of Pharmacy, Sahmyook University, Seoul, Korea
6 shared publicationsJae Hoon Cheong
School of Pharmacy, Sahmyook University, Seoul, Korea
4 shared publications- Jonathan B. Coulter
Johns Hopkins School of Medicine
4 shared publications Tamal Chakraborti
Department of Neurology, Kennedy Krieger Research Institute, Baltimore, Maryland
4 shared publicationsYongbae Kim
Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, USA
4 shared publicationsCliona O'DRiscoll
3 shared publications
Latest Publications
- 1 January 2021
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 410, 115354
Ethyl maltol enhances copper mediated cytotoxicity in lung epithelial cells
- 1 January 2021
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 410, 115354
Ethyl maltol enhances copper mediated cytotoxicity in lung epithelial cells
- Open Access
- 1 June 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-11
Measuring Cancer Hallmark Mediation of the TET1 Glioma Survival Effect with Linked Neural-Network Based Mediation Experiments
This paper examines the effect of TET1 expression on survival in glioma patients using open-access data from the Genomic Data Commons. A neural network-based survival model was built on expression data from a selection of genes most affected by TET1 knockdown with a median cross-validated survival concordance of 82.5%. A synthetic experiment was then conducted that linked two separately trained neural networks: a multitask model estimating cancer hallmark gene expression from TET1 expression, and a survival neural network. This experiment quantified the mediation of the TET1 survival effect through eight cancer hallmarks: apoptosis, cell cycle, cell death, cell motility, DNA repair, immune response, two phosphorylation pathways, and a randomized gene sets. Immune response, DNA repair, and apoptosis displayed greater mediation than the randomized gene set. Cell motility was inversely associated with only 12.5% mediated concordance. We propose the neural network linkage mediation experiment as an approach to collecting evidence of hazard mediation relationships with prognostic capacity useful for designing interventions.
- 1 June 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-11
Open AccessMeasuring Cancer Hallmark Mediation of the TET1 Glioma Survival Effect with Linked Neural-Network Based Mediation Experiments
This paper examines the effect of TET1 expression on survival in glioma patients using open-access data from the Genomic Data Commons. A neural network-based survival model was built on expression data from a selection of genes most affected by TET1 knockdown with a median cross-validated survival concordance of 82.5%. A synthetic experiment was then conducted that linked two separately trained neural networks: a multitask model estimating cancer hallmark gene expression from TET1 expression, and a survival neural network. This experiment quantified the mediation of the TET1 survival effect through eight cancer hallmarks: apoptosis, cell cycle, cell death, cell motility, DNA repair, immune response, two phosphorylation pathways, and a randomized gene sets. Immune response, DNA repair, and apoptosis displayed greater mediation than the randomized gene set. Cell motility was inversely associated with only 12.5% mediated concordance. We propose the neural network linkage mediation experiment as an approach to collecting evidence of hazard mediation relationships with prognostic capacity useful for designing interventions.
- 1 October 2019
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 380, 114646
TET1 regulates DNA repair in human glial cells
- 1 October 2019
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 380, 114646
TET1 regulates DNA repair in human glial cells
- 3 October 2017
- Published by Taylor & Francis in Epigenetics
- Vol. 12 (10) , 854-864
TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents
Recent studies have shown that loss of TET1 may play a significant role in the formation of tumors. Because genomic instability is a hallmark of cancer, we examined the potential involvement of 10-11 translocation 1 (TET1) in the DNA damage response (DDR). Here we demonstrate that, in response to clinically relevant doses of ionizing radiation (IR), human glial cells made TET1-deficient with lentiviral vectors displayed greater numbers of colony forming units and lower levels of apoptotic markers compared with glial cells transduced with control vectors; yet, they harbored greater DNA strand breaks. The G2/M check point and expression of cyclin B1 were greatly diminished in TET1-deficient cells, and TET1-deficient cells displayed lower levels of γH2A.x following exposure to IR. Levels of DNA-PKcs, which are DNA-PK complex members, were lower in TET1-deficient cells compared with control cell lines. However, levels of ATM were similar in both cell lines. Cyclin B1, DNA-PKcs, and γH2A.x levels were each rescued by reintroduction of the TET1 catalytic domain. Finally, cytosine methylation within intron 1 of PRKDC, the gene encoding DNA-PKcs, was significantly higher upon depletion of TET1. Taken together, this study illustrates the involvement of TET1 in the different arms of the DDR and suggests its loss results in the continued survival of cells with genomic instability.
- 3 October 2017
- Published by Taylor & Francis in Epigenetics
- Vol. 12 (10) , 854-864
TET1 deficiency attenuates the DNA damage response and promotes resistance to DNA damaging agents
Recent studies have shown that loss of TET1 may play a significant role in the formation of tumors. Because genomic instability is a hallmark of cancer, we examined the potential involvement of 10-11 translocation 1 (TET1) in the DNA damage response (DDR). Here we demonstrate that, in response to clinically relevant doses of ionizing radiation (IR), human glial cells made TET1-deficient with lentiviral vectors displayed greater numbers of colony forming units and lower levels of apoptotic markers compared with glial cells transduced with control vectors; yet, they harbored greater DNA strand breaks. The G2/M check point and expression of cyclin B1 were greatly diminished in TET1-deficient cells, and TET1-deficient cells displayed lower levels of γH2A.x following exposure to IR. Levels of DNA-PKcs, which are DNA-PK complex members, were lower in TET1-deficient cells compared with control cell lines. However, levels of ATM were similar in both cell lines. Cyclin B1, DNA-PKcs, and γH2A.x levels were each rescued by reintroduction of the TET1 catalytic domain. Finally, cytosine methylation within intron 1 of PRKDC, the gene encoding DNA-PKcs, was significantly higher upon depletion of TET1. Taken together, this study illustrates the involvement of TET1 in the different arms of the DDR and suggests its loss results in the continued survival of cells with genomic instability.
- Open Access
- 29 March 2017
- Published by Springer Nature in Clinical Epigenetics
- Vol. 9 (1) , 1-8
Associations of LEP, CRH, ICAM-1, and LINE-1 methylation, measured in saliva, with waist circumference, body mass index, and percent body fat in mid-childhood
Genetics explains a small proportion of variance in body mass index at the population level. Epigenetics, commonly measured by gene methylation, holds promise for understanding obesity risk factors and mechanisms. Participants were 431 adolescents aged 10–15 years. BMI z-score, waist circumference z-score, and percent body fat were measured. Saliva samples were collected and methylation of promoter regions of four candidate genes or sequences (LEP, ICAM-1, CRH, and LINE-1) were measured in 3–4 CpG sites each. Linear regression was used to identify associations of methylation with obesity-related outcomes. After adjusting for age, in sex-stratified analysis, the three obesity-related outcomes were negatively associated with LEP methylation in obese boys only. There were no associations of methylation of the other genes or sequences and the obesity-related outcomes. Our results are consistent with prior studies that reported sex differences in associations of obesity-related outcomes with LEP methylation, and also as would be expected in adipose tissue, the source of circulating leptin. The findings suggest that saliva might be an acceptable tissue for epigenetics studies in adolescents.
- 29 March 2017
- Published by Springer Nature in Clinical Epigenetics
- Vol. 9 (1) , 1-8
Open AccessAssociations of LEP, CRH, ICAM-1, and LINE-1 methylation, measured in saliva, with waist circumference, body mass index, and percent body fat in mid-childhood
Genetics explains a small proportion of variance in body mass index at the population level. Epigenetics, commonly measured by gene methylation, holds promise for understanding obesity risk factors and mechanisms. Participants were 431 adolescents aged 10–15 years. BMI z-score, waist circumference z-score, and percent body fat were measured. Saliva samples were collected and methylation of promoter regions of four candidate genes or sequences (LEP, ICAM-1, CRH, and LINE-1) were measured in 3–4 CpG sites each. Linear regression was used to identify associations of methylation with obesity-related outcomes. After adjusting for age, in sex-stratified analysis, the three obesity-related outcomes were negatively associated with LEP methylation in obese boys only. There were no associations of methylation of the other genes or sequences and the obesity-related outcomes. Our results are consistent with prior studies that reported sex differences in associations of obesity-related outcomes with LEP methylation, and also as would be expected in adipose tissue, the source of circulating leptin. The findings suggest that saliva might be an acceptable tissue for epigenetics studies in adolescents.
- 30 July 2015
- Published by IOS Press in Journal of Pediatric Neurology
- Vol. 09 (01) , 001-008
Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism
Fluoxetine, a selective serotonin reuptake inhibitor, has shown favorable effects in some children with autism. There are no previous studies evaluating the connection between clinical outcome and markers of clinical response to fluoxetine treatment. In this prospective clinical trial we examined serum brain derived neurotrophic factor (BDNF) concentrations and serotonin transporter (SERT) binding in the medial frontal cortex and the midbrain, measured by single photon emission computed tomography scanning, in a group of 13 autistic children and adolescents (12 males; age 5–16 years), who were treated for 6 months with fluoxetine at a dose range of 10–40 mg/day. Clinical response was evaluated by the Autism Treatment Evaluation Checklist. Serum concentrations of BDNF and SERT binding were measured at baseline and 2 months after termination of fluoxetine treatment. At baseline, before starting fluoxetine treatment, the serum concentration of BDNF had a bimodal distribution in the autism group with either a low concentration (n = 8, mean 1497 pg/mL) or a high concentration (n = 5, mean 14062 pg/mL) with respect to controls (n = 15, mean 9652 pg/mL), and SERT binding was uniformly low in the autistic subjects in the medial frontal cortex and the midbrain. Fluoxetine treatment led to positive effects in several aspects of communication, socialization and cognitive awareness, with six out 13 subjects being particularly good responders. These six also had a significant decrease in BDNF (P = 0.03) and minimal change in SERT binding after therapy. The other seven subjects showed a trend towards an increase in BDNF and SERT binding. Our results indicate that fluoxetine may improve core autistic symptoms, and that this clinical response is linked to a decrease in serum BDNF.
- 30 July 2015
- Published by IOS Press in Journal of Pediatric Neurology
- Vol. 09 (01) , 001-008
Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism
Fluoxetine, a selective serotonin reuptake inhibitor, has shown favorable effects in some children with autism. There are no previous studies evaluating the connection between clinical outcome and markers of clinical response to fluoxetine treatment. In this prospective clinical trial we examined serum brain derived neurotrophic factor (BDNF) concentrations and serotonin transporter (SERT) binding in the medial frontal cortex and the midbrain, measured by single photon emission computed tomography scanning, in a group of 13 autistic children and adolescents (12 males; age 5–16 years), who were treated for 6 months with fluoxetine at a dose range of 10–40 mg/day. Clinical response was evaluated by the Autism Treatment Evaluation Checklist. Serum concentrations of BDNF and SERT binding were measured at baseline and 2 months after termination of fluoxetine treatment. At baseline, before starting fluoxetine treatment, the serum concentration of BDNF had a bimodal distribution in the autism group with either a low concentration (n = 8, mean 1497 pg/mL) or a high concentration (n = 5, mean 14062 pg/mL) with respect to controls (n = 15, mean 9652 pg/mL), and SERT binding was uniformly low in the autistic subjects in the medial frontal cortex and the midbrain. Fluoxetine treatment led to positive effects in several aspects of communication, socialization and cognitive awareness, with six out 13 subjects being particularly good responders. These six also had a significant decrease in BDNF (P = 0.03) and minimal change in SERT binding after therapy. The other seven subjects showed a trend towards an increase in BDNF and SERT binding. Our results indicate that fluoxetine may improve core autistic symptoms, and that this clinical response is linked to a decrease in serum BDNF.
- 1 June 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 283, 23-29
Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells
- 1 June 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 283, 23-29
Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells
- Open Access
- 1 October 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (40) , 28792-28800
Hydroquinone Increases 5-Hydroxymethylcytosine Formation through Ten Eleven Translocation 1 (TET1) 5-Methylcytosine Dioxygenase
- 1 October 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (40) , 28792-28800
Open AccessHydroquinone Increases 5-Hydroxymethylcytosine Formation through Ten Eleven Translocation 1 (TET1) 5-Methylcytosine Dioxygenase
- 31 March 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1833 (3) , 460-467
Induction of a trophoblast-like phenotype by hydralazine in the p19 embryonic carcinoma cell line
- 31 March 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1833 (3) , 460-467
Induction of a trophoblast-like phenotype by hydralazine in the p19 embryonic carcinoma cell line
- 1 January 2013
- Published by Elsevier in Brain Research
- Vol. 1490, 35-42
Relationship between Mecp2 and NFκb signaling during neural differentiation of P19 cells
- 1 January 2013
- Published by Elsevier in Brain Research
- Vol. 1490, 35-42
Relationship between Mecp2 and NFκb signaling during neural differentiation of P19 cells